First-in-the-world Regeneron trial began at Holy Name Medical Center, Teaneck

Findings on the efficacy of the experimental antibody cocktail could be critical to the future of treatment

One of the treatments President Donald Trump received while at Walter Reed Medical Center is an experimental “antibody cocktail” made by the pharmaceutical company Regeneron. The drug is not approved by the Food and Drug Administration, but reportedly is one of the most promising therapies available.

Holy Name Medical Center in Teaneck, once the epicenter of New Jersey’s COVID-19 outbreak, was the first hospital in the world to enroll a patient in a Regeneron trial. As Correspondent Michael Hill reports, the findings could be critical to the president’s recovery and the future of treatment.